These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1704437)

  • 21. The effects of ancrod, the coagulating enzyme from the venom of Malayan pit viper (A. rhodostoma) on prothrombin and fibrinogen metabolism and fibrinopeptide A release in man.
    Bell WR; Shapiro SS; Martinez J; Nossel HL
    J Lab Clin Med; 1978 Apr; 91(4):592-604. PubMed ID: 641385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mo1, anti-CD11b) that inhibits leukocyte adhesion.
    Simpson PJ; Todd RF; Fantone JC; Mickelson JK; Griffin JD; Lucchesi BR
    J Clin Invest; 1988 Feb; 81(2):624-9. PubMed ID: 3339135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel hemoglobin-based blood substitute protects against myocardial reperfusion injury.
    Caswell JE; Strange MB; Rimmer DM; Gibson MF; Cole P; Lefer DJ
    Am J Physiol Heart Circ Physiol; 2005 Apr; 288(4):H1796-801. PubMed ID: 15772335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Platelet aggregation following defibrination with ancrod.
    Slade CL; Andes WA; Mason AD
    Thromb Haemost; 1976 Nov; 36(2):424-9. PubMed ID: 1036842
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardioprotection and thrombolysis by anistreplase in anesthetized dogs.
    Feuerstein GZ; Nichols AJ; Valocik RE; Gagnon R; Sellars TS; Fears RC; Ferres H; Ruffolo RR
    J Cardiovasc Pharmacol; 1995 Apr; 25(4):625-33. PubMed ID: 7596132
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Iloprost inhibits neutrophil function in vitro and in vivo and limits experimental infarct size in canine heart.
    Simpson PJ; Mickelson J; Fantone JC; Gallagher KP; Lucchesi BR
    Circ Res; 1987 May; 60(5):666-73. PubMed ID: 2439229
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myeloperoxidase activity as a quantitative marker of polymorphonuclear leukocyte accumulation into an experimental myocardial infarct--the effect of ibuprofen on infarct size and polymorphonuclear leukocyte accumulation.
    Allan G; Bhattacherjee P; Brook CD; Read NG; Parke AJ
    J Cardiovasc Pharmacol; 1985; 7(6):1154-60. PubMed ID: 2418303
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Thrombotic arterial and venous obstructions under ancrod (Arwin) therapy (author's transl)].
    Heidrich H
    Med Klin; 1978 May; 73(21):798-800. PubMed ID: 651769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protection of the ischaemic myocardium from reperfusion injury by defibrotide and its possible mechanism of action.
    Thiemermann C; Ney P; Schrör K
    Biomed Biochim Acta; 1988; 47(10-11):S19-22. PubMed ID: 3248105
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of bepridil on regional and global myocardial ischemia/reperfusion-induced injury.
    Jackson CV; Mitsos SE; Simpson PJ; Driscoll EM; Lucchesi BR
    Pharmacology; 1985; 30(6):320-32. PubMed ID: 3874404
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myocardial infarction and purine transport inhibition in anaesthetised ferrets.
    Poucher SM; Brooks R; Pleeth RM; Conant AR; Collis MG
    Eur J Pharmacol; 1994 Jan; 252(1):19-27. PubMed ID: 8149993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protection of reperfused ischemic canine myocardium by CI-922, a new inhibitor of leukocyte activation.
    Werns SW; Eller BT; Shea MJ; Simpson PJ; Dysko RC; Abrams GD; Lucchesi BR
    J Cardiovasc Pharmacol; 1988; 12(5):608-14. PubMed ID: 2468062
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of defibrination on tumor growth and response to chemotherapy.
    DeWys WD; Kwaan HC; Bathina S
    Cancer Res; 1976 Oct; 36(10):3584-7. PubMed ID: 953985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improvement in blood flow through a critical arterial stenosis by defibrination with ancrod.
    Barrie WW; Schenk WG
    Arch Surg; 1976 May; 111(5):561-3. PubMed ID: 1267605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Defibrinogenating enzymes.
    Bell WR
    Drugs; 1997; 54 Suppl 3():18-30; discussion 30-1. PubMed ID: 9360849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of ancrod and heparin as anticoagulants following endarterectomy in the dog.
    Daniel TM; Pizzo SV; Mckee PA
    Ann Surg; 1976 Aug; 184(2):223-8. PubMed ID: 952568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of severe foot ischaemia by defibrination with ancrod: a randomized blind study.
    Tønnesen KH; Sager P; Gormsen J
    Scand J Clin Lab Invest; 1978 Sep; 38(5):431-5. PubMed ID: 360366
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decreased myocardial fibrinolytic activity following temporary ischaemia and reperfusion.
    Cherry GW; Opie LH
    Thromb Diath Haemorrh; 1975 Sep; 34(1):210-5. PubMed ID: 810911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasminogen activation without changes in tPA and PAI-1 in response to subcutaneous administration of ancrod.
    Dempfle CE; Alesci S; Kucher K; Müller-Peltzer H; Rübsamen K; Borggrefe M
    Thromb Res; 2001 Dec; 104(6):433-8. PubMed ID: 11755954
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subcutaneous ancrod after operation for fractured hip--a dose-ranging and feasibility study.
    Lowe GD; Morrice JJ; Fulton A; Forbes CD; Prentice CR; Barbenel JC
    Thromb Haemost; 1978 Aug; 40(1):134-43. PubMed ID: 725844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.